Core Points - The company is holding its first extraordinary general meeting of shareholders in 2025 to discuss key proposals [1][4] - The meeting will address the completion of certain fundraising investment projects and the allocation of surplus funds to enhance liquidity [4][5] - The company plans to cancel its supervisory board and amend its articles of association, transferring supervisory responsibilities to the audit committee [6][7] Group 1: Meeting Procedures - Shareholders and their representatives must sign in 30 minutes before the meeting and present necessary identification documents [2] - Only authorized personnel, including shareholders, directors, and invited guests, are allowed to attend the meeting [3] - The meeting will be conducted with strict order, and any disruptive behavior will be addressed by staff [3][4] Group 2: Proposals - Proposal 1: The company intends to allocate surplus funds of 104.7854 million yuan from the "Medical Equipment and Biological Testing Reagent Industrialization Project" to enhance liquidity, having already invested 390.2415 million yuan out of the planned 486.6919 million yuan [5] - Proposal 2: The company proposes to abolish the supervisory board and allow the audit committee to assume its responsibilities, with necessary amendments to the articles of association [6][7] - Proposal 3: The company aims to revise and establish certain internal governance systems to align with the latest regulations and improve operational standards [7]

Summary of Key Points Core Viewpoint - The company has completed certain fundraising investment projects and plans to permanently supplement its working capital with the surplus funds from these projects [1][4]. Fundraising Basic Situation - The company issued 23,290,278 shares at a price of RMB 48.98 per share, raising a total of RMB 1,140.7578 million, with a net amount of RMB 1,054.3036 million after deducting issuance costs [2][3]. Investment Project Situation - The total planned investment for the fundraising projects was RMB 999.984 million, with RMB 985.6759 million allocated from the raised funds [2][3]. Surplus Funds Usage and Reasons - The surplus funds from the "Medical Devices and Biological Testing Reagent Industrialization Project" will be permanently used to supplement working capital, with the remaining funds to cover outstanding payments such as salaries and bonuses [3][4]. - The surplus was achieved through strict adherence to fundraising regulations, cost control, and efficient resource allocation during project implementation [3][4]. Approval Process - The decision to conclude the fundraising project and allocate surplus funds was approved by the company's board and will be submitted for shareholder meeting approval [4][6]. Supervisory Opinions - The supervisory board confirmed that the decision aligns with relevant regulations and is in the best interest of the company and its shareholders, ensuring no adverse impact on operations [4][6]. Sponsor's Verification Opinion - The sponsor, CITIC Securities, has no objections to the company's decision regarding the conclusion of the fundraising project and the allocation of surplus funds, confirming compliance with regulatory requirements [5][6].